Quantum Labs
Bahasa Melayu
CJC-1295 + Ipamorelin 5 mg + 5 mgPek 10 vial6 stokJimat 22%
Pilihan utamapeptideintermediate6 stok

CJC-1295 + Ipamorelin 5 mg + 5 mg

Gabungan klasik GHRH + mimetik ghrelin

CJC-1295 and Ipamorelin research stack, Australian-shipped. Lab-verified to ≥99% purity.

Dos
5mg + 5mg / vial
Bentuk
Serbuk liofilisasi
Pek
Pek 10 vial

Untuk tujuan penyelidikan sahaja. Sebatian ini dijual secara ketat untuk penyelidikan in-vitro dan tujuan makmal, dan tidak dimaksudkan untuk kegunaan manusia atau penggunaan terapeutik. Dengan membeli, anda mengesahkan bahawa anda ialah penyelidik yang berkelayakan dan bersetuju dengan penafian penuh kami.

RM 880 MYR
Jimat 22%
Pek 10 vial
Dulu RM 1,128 MYR
Dijual sebagai pek 10 vial

Tinggal 6 pek sahaja

🧪Disahkan makmal
✓Diuji pihak ketiga
⚡Penghantaran seluruh dunia yang pantas
🔒Pembayaran kad yang selamat
Gambaran keseluruhan

Vial penyelidikan gabungan yang memasangkan analog GHRH CJC-1295 dengan mimetik ghrelin terpilih Ipamorelin. Gabungan sekretagog GH dwi-mekanisme yang paling banyak dikaji dalam penyelidikan peptida.

CJC-1295 and Ipamorelin are a long-standing pair in growth-hormone secretagogue research. CJC-1295 is a 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH); Ipamorelin is a selective ghrelin receptor agonist (a 'GHS' or growth-hormone secretagogue). The two compounds act on different receptors but converge on the somatotrophs of the anterior pituitary, where they amplify pulsatile growth-hormone release in pre-clinical models.

Quantum Labs supplies the pair as a pre-portioned research stack — two lyophilised vials shipped together, each HPLC-verified to ≥99% purity. Australian-shipped from local stock; supplied for laboratory research use only.

Mekanisme

CJC-1295 menyokong isyarat reseptor GHRH asas, manakala Ipamorelin memacu denyut reseptor ghrelin terpilih. Penyelidikan menunjukkan corak pelepasan GH yang sinergi dan hampir fisiologi pada subjek kajian.

Laporan makmal

Disahkan HPLC terhadap spesifikasi ketulenan ≥99%. Diuji secara bebas oleh makmal pihak ketiga bertauliah.

CJC-1295: DAC vs no-DAC

CJC-1295 exists in two research forms: with Drug Affinity Complex (DAC) and without. The DAC variant binds albumin in plasma, extending the half-life from minutes to days. Research designs targeting acute pulsatile GH release typically use the no-DAC form (modified GRF 1-29); studies modelling sustained GH elevation use the DAC variant. Our supply is the no-DAC research-grade form unless otherwise specified.

Soalan lazim penyelidik

CJC-1295 + Ipamorelin — soalan lazim

What is the CJC-1295 + Ipamorelin stack?

It is a research pairing of two growth-hormone secretagogues: CJC-1295 (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist). The two compounds act on different receptors but converge on stimulating pulsatile growth-hormone release in pre-clinical models.

How does CJC-1295 differ from Ipamorelin?

CJC-1295 mimics growth-hormone-releasing hormone (GHRH), binding the GHRH receptor on pituitary somatotrophs. Ipamorelin mimics ghrelin, binding the growth-hormone secretagogue receptor (GHSR-1a). The two pathways are independent but synergistic — combining them produces a larger pulsatile GH response in research models than either compound alone.

Is CJC-1295 + Ipamorelin legal in Australia?

Both compounds are restricted for human therapeutic supply in Australia and remain available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies the stack for research use only.

What does selective mean for Ipamorelin?

Ipamorelin is described as a selective ghrelin agonist because it activates the GH-release pathway with minimal effect on cortisol, prolactin, or aldosterone — distinguishing it from earlier-generation GHS molecules. This selectivity has made it a preferred research tool for isolating GH-specific effects.

What is the typical CJC-1295 + Ipamorelin research dosage?

Published research protocols have used wide dose ranges depending on the model and species. Human dosing is not established. Researchers should consult primary literature for protocol-specific guidance.

Are CJC-1295 and Ipamorelin used together?

Yes — combined-administration research is common precisely because the two compounds act on independent receptors and produce a synergistic GH-release response. The combination is a standard tool in growth-hormone secretagogue research.

Bacaan lanjut

Panduan berkaitan CJC-1295 + Ipamorelin

Sebatian berkaitan

Penyelidik juga meneliti